Clinical trials: Chronic Obstruct Airways Disease
Pulmonary Disease, Chronic Obstructive
Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase IV multi-center, randomized, open-label, cross-over, placebo study in subjects with Chronic Obstructive Pulmonary Disease (COPD) to compare inhaler-specific preference attributes of two inhalers - ELLIPTA dry…
- Trial name
- NCT02786927
- Testing
- Inhaler Preference Questionnaire Version 1, Inhaler Preference Questionnaire Version 2
- Where
- 22 sites in United States
- Volunteers
- 214 people
- Sponsor
- GlaxoSmithKline
COPD (Chronic Obstructive Pulmonary Disease)
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD.
- Trial name
- STRIDE (NCT07612878)
- Testing
- Cohort 1: Dupilumab, Cohort 2: usual care only
- Where
- 7 sites in United States
- Volunteers
- 350 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease
MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA
This is a retrospective-prospective, non-interventional, multi-centre study that will be conducted in routine clinical settings in Russia.
- Trial name
- MINERVA (NCT06422676)
- Where
- 14 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy Study of the Effect of Budesonide on Emphysema
To assess the effect of up to 4 years treatment with budesonide on progression of emphysema in patients with Chronic Obstructive Lung Disease.
- Trial name
- NCT00232674
- Testing
- Pulmicort (budesonide) Turbuhaler
- Where
- Denmark
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS
This study is to evaluate if add-on treatment with inhaled NVA237 (50 µg) once daily (o.d.) via single-dose dry-powder inhaler (SDDPI) further improves lung function and health status and is well tolerated compared to placebo in…
- Trial name
- GLOW8 (NCT01757015)
- Testing
- NVA237
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease
To collect post-marketing safety and effectiveness information on the use of Tiotropium Inhalation Capsules (18 μg) in patients with chronic obstructive pulmonary disease in daily clinical settings
- Trial name
- COPD (NCT02177318)
- Testing
- Spiriva (tiotropium bromide) inhalation capsules
- Where
- 418 sites in Japan
- Volunteers
- 3,588 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers
The purpose of the study is to obtain pharmacokinetics, safety and tolerability data after single administrations of CHF6001 in subjects with mild, moderate and severe renal impairment as well as healthy volunteers under the same…
- Trial name
- NCT05431426
- Testing
- CH6001
- Where
- Bulgaria
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.
This study will involve the use of a new compound, GW642444 that is being developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00519376
- Testing
- GW642444M, GW642444H
- Where
- 4 sites in Germany
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
12-week Efficacy of Indacaterol
This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.
- Trial name
- NCT01072448
- Testing
- Indacaterol 75 μg
- Where
- 62 sites in United States
- Volunteers
- 323 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease (COPD).
Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069
Study to investigate safety, tolerability and effect of multiple dosing with AZD 4721 and/or with AZD 5069
- Trial name
- NCT01962935
- Testing
- AZD4721, AZD5069
- Where
- United Kingdom
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD
The purpose of this study is to evaluate discontinuation rates of roflumilast using an up-titration regimen for the first 4 weeks of treatment compared with continuous treatment of 500 μg one daily (OD) during the entire 12-week…
- Trial name
- OPTIMIZE (NCT02165826)
- Testing
- Roflumilast, Standard of Care COPD Treatment
- Where
- 2 sites in Slovakia
- Volunteers
- 1,323 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study to Investigate the Association of Real-world Sensor-derived Biometric Data With Clinical Parameters and Patient-reported Outcomes for Monitoring Disease Activity in Patients With COPD
The purpose of this multicenter, prospective cohort study is to investigate the correlation of real-world sensor-derived biometric data obtained via a wearable device with clinical parameters and patient-reported outcomes (PROs)…
- Trial name
- NCT05655832
- Testing
- Vivalink wearable device
- Where
- 11 sites in Germany
- Volunteers
- 77 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Pulmonary Disease, Chronic Obstructive
Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease
GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00515502
- Testing
- GSK573719, Tiotropium
- Where
- 3 sites in Germany
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks
This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.
- Trial name
- NCT01068600
- Testing
- Indacaterol
- Where
- 54 sites in United States
- Volunteers
- 318 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
High Dose Trial in COPD
The primary objective of this study was to compare the efficacy and safety of 200 μg and 400 μg of BEA 2180 BR to tiotropium 5 μg and placebo when each was delivered by the Respimat® Inhaler once daily for four weeks in patients…
- Trial name
- NCT00128440
- Testing
- BEA 2180 BR, tiotropium
- Where
- 13 sites in United States
- Volunteers
- 78 people
- Sponsor
- Boehringer Ingelheim
COPD
Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)
To evaluate changes in activity based on the use of portable oxygen concentrators combined with standard of care (SOC) long- term oxygen therapy versus SOC long-term oxygen therapy alone at 12 weeks in patients with COPD who…
- Trial name
- POC-STEP (NCT03513068)
- Testing
- Portable Oxygen Concentrator (POC)
- Where
- 11 sites in United States
- Volunteers
- 108 people
- Sponsor
- ResMed
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary purpose of the study is to investigate if Symbicort is more effective than Oxis in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in patients with COPD.
- Trial name
- SUMIRE (NCT01069289)
- Testing
- Budesonide/formoterol (Symbicort Turbuhaler), Formoterol (Oxis Turbuhaler)
- Where
- 119 sites in India, Japan and 7 more
- Volunteers
- 1,293 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components…
- Trial name
- NCT01431287
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 240 sites in United States, Austria and 22 more
- Volunteers
- 2,539 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Main Study: To evaluate and to compare the lung function response to the free combinations of tiotropium 18 μg (QD) + salmeterol 50 μg (QD or BID), salmeterol 50 μg BID and tiotropium 18 μg QD at the end of 6-week treatment…
- Trial name
- NCT02242253
- Testing
- Tiotropium, Salmeterol
- Volunteers
- 97 people
- Sponsor
- Boehringer Ingelheim
Emphysema
STRIVE Post-Market Registry Study
This is a single-arm, prospective, multi-center, Registry study to evaluate the long-term safety and effectiveness of the Spiration Valve System (SVS) for the treatment of severe emphysema in a post-market setting.
- Trial name
- NCT04302272
- Testing
- Spiration Valve System (SVS)
- Where
- 16 sites in United States
- Volunteers
- 150 people
- Sponsor
- Olympus Corporation of the Americas
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.